ASH Letter on FDA Draft Guidance on Diversity Plans to Improve Enrollment in Clinical Trials
Jun 13
2022
American Society of Hematology. (2022).
ASH Letter on FDA Draft Guidance on Diversity Plans to Improve Enrollment in Clinical Trials.
Retrieved from https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-on-fda-draft-guidance-on-diversity-plans-to-improve-enrollment-in-clinical-trials.
American Society of Hematology.
"ASH Letter on FDA Draft Guidance on Diversity Plans to Improve Enrollment in Clinical Trials." Hematology.org.
https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-on-fda-draft-guidance-on-diversity-plans-to-improve-enrollment-in-clinical-trials
(label-accessed May 30, 2025).
"American Society of Hematology."
ASH Letter on FDA Draft Guidance on Diversity Plans to Improve Enrollment in Clinical Trials, 30 May. 2025 ,
https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-on-fda-draft-guidance-on-diversity-plans-to-improve-enrollment-in-clinical-trials.
